Read Full Article
PARIS/LONDON (Reuters) - Chris Viehbacher speaks plainly. "We had somewhat of a mess in Brazil," he told financial analysts in August 2013, "so that's why I decided to change management...
We had a conference call and questions were asked about his position but he was being reassuring.
The execution focus was not sufficient.
Chris's management style was not adequate.
As CEO, do not try to sell an $8 billion drug portfolio without informing your board, if you want to keep your job!
The strategic direction of the company is now much more uncertain.